Molbio Diagnostics Ltd
Molbio Diagnostics Q2 Results 2026 (FY27): Revenue ₹259.0 Cr, EBITDA margin 29.0%
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹259Cr
- +159.8% YoY
- Net profit
- ₹8Cr
- Q1 FY26: −₹24 Cr
- Margin
- 16.97%
- +33.1 pp YoY
Guidance rank: #3 of 13 in Healthcare Equipment & Supplies
See the sector's top 10 — free with your mobile number.
Based on Molbio Diagnostics Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue from Operations: ₹259.0 Cr vs ₹580.3 Cr in Q2 FY26 (significant decrease due to rate contract negotiations). Quarterly EBITDA:.
From Molbio Diagnostics Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.
How did Molbio Diagnostics' revenue grow in the September 2026 quarter?
- Q2 FY27 Revenue from Operations: ₹259.0 Cr vs ₹580.3 Cr in Q2 FY26 (significant decrease due to rate contract negotiations).
- Truenat devices sold Q2 FY27: 395 units vs 647 units in Q2 FY26.
- Truenat test kits sold Q2 FY27: 3.24 million units vs 8.73 million units in Q2 FY26.
- EBITDA for Q2 FY27: ₹49.7 Cr (18.8% margin) vs ₹168.5 Cr (29.0% margin) in Q2 FY26.
- PAT for Q2 FY27: ₹7.7 Cr (2.9% margin) vs ₹106.8 Cr (18.4% margin) in Q2 FY26.
- H1 FY27 Total Income: ₹676.3 Cr vs ₹681.8 Cr in H1 FY26.
- H1 FY27 Devices sold: 559 units vs 860 units in H1 FY26.
2 more points from Molbio Diagnostics Ltd's call on revenue
Create a free account to keep reading this call
What happened to Molbio Diagnostics' margins in Q2 FY27?
See what Molbio Diagnostics Ltd said on profitability & margins — free account, 30 seconds.
What capex is Molbio Diagnostics planning?
- Page 17 describes a scaled, multi-location manufacturing footprint with 6 facilities across 4 locations (Goa, Visakhapatnam, Bengaluru, Pune) supporting Truenat® Test Kits, devices, and digital pathology scanners.
- FY26 utilisation rates: 58.25% for Test Kits plant, 42.3% for Devices plant, indicating available headroom for growth.
- Early investments in capacity provide headroom to support future growth, combining in-house manufacturing and outsourced EMS partners for flexibility and scalability.
2 more points from Molbio Diagnostics Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Molbio Diagnostics raising money or cutting debt?
See what Molbio Diagnostics Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Molbio Diagnostics' order book?
See what Molbio Diagnostics Ltd said on order book & pipeline — free account, 30 seconds.
Molbio Diagnostics Ltd — Quarterly revenue & net profit
Molbio Diagnostics Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q1 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 259 | 100 | +159.8% | 408 | -36.6% |
| Operating profit (EBITDA) | 44 | -16 | — | 101 | -56.3% |
| Operating margin | 16.97% | -16.16% | +33.1 pp | 24.63% | -7.7 pp |
| Profit before tax | 18 | -31 | — | 76 | -76.9% |
| Net profit (PAT) | 8 | -24 | — | 53 | -85.4% |
| EPS (₹) | 1.31 | -2.10 | — | 5.21 | -74.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹259 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Molbio Diagnosti's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Vasa Denticity (Q2 FY27)
Year-on-year revenue growth: Approximately 95.3% increase in revenue from Rs. Key results statement takeaways from Vasa Denticity Ltd's Q2 FY27 results statemen
- Vaidya Sane (Q2 FY27)
Year-on-year (YoY) change: +23% (from INR 687 Lakhs in Sep 2025) . Key results statement takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q2 FY27 results s
- Sahajanand Medi (Q2 FY27)
Slight seasonality in revenue with H2 being marginally higher (~52%) than H1 (~48%). Key concall takeaways from Sahajanand Medical Technologies Ltd's Q2 FY27…
- Poly Medicure (Q2 FY27)
Q2 FY27 consolidated revenue from operations: Rs 580.5 Cr, up 30.8% YoY (Q2 FY26: Rs 443.9 Cr). Key investor presentation takeaways from Poly Medicure Ltd's Q2
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- 3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Molbio Diagnostics Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Molbio Diagnostics Ltd Q2 FY27 results?
Q2 FY27 Revenue from Operations: ₹259.0 Cr vs ₹580.3 Cr in Q2 FY26 (significant decrease due to rate contract negotiations). Quarterly EBITDA:.
What is Molbio Diagnostics Ltd share price analysis?
Molbio Diagnostics Ltd currently shows a neutral. The stock trades at a P/E of 73.3 with a market cap of ₹15,924 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Molbio Diagnostics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.